Common Contracts
2 similar Collaboration and License Agreement contracts by ChemoCentryx, Inc.
Vifor (International) Ltd. Rechenstrasse 37 CH-9014 St. Gallen SwitzerlandCollaboration and License Agreement • August 9th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations
As you know, Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and ChemoCentryx, Inc. (“ChemoCentryx”) are parties to that certain Collaboration and License Agreement, dated December 22, 2016 (the “VFMCRP Agreement”), pursuant to which ChemoCentryx granted VFMCRP an exclusive license to commercialize ChemoCentryx’s proprietary C5aR inhibitor known as CCX140 in certain countries. Capitalized terms used but not otherwise defined in this letter agreement (this “Letter”) will have the meanings provided in the VFMCRP Agreement. The VFMCRP Agreement was originally entered into between Vifor (International) Ltd. (“Vifor”) and ChemoCentryx and was subsequently assigned by Vifor to VFMCRP, so that references in the VFMCRP Agreement to VIT now refer to VFMCRP.
Vifor (International) Ltd. Rechenstrasse 37 CH-9014 St. Gallen SwitzerlandCollaboration and License Agreement • August 9th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations
As you know, Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and ChemoCentryx, Inc. (“ChemoCentryx”) are parties to that certain Collaboration and License Agreement, dated May 9, 2016, amended May 22, 2017 (the “VFMCRP Agreement”), pursuant to which ChemoCentryx granted VFMCRP an exclusive license to commercialize ChemoCentryx’s proprietary C5aR inhibitor known as CCX168 in certain countries. ChemoCentryx and Vifor (International) Ltd. (“Vifor”) have entered into a Letter Agreement on 10 February 2017 to expand the territory and to grant an option to Vifor to include China in the territory upon payment of five million U.S. dollars (the “LA1”). Capitalized terms used but not otherwise defined in this letter agreement (this “Letter”) will have the meanings provided in the VFMCRP Agreement. The VFMCRP Agreement and the LA1 were originally entered into between Vifor (International) Ltd. (“Vifor”) and ChemoCentryx and were subsequently assigned by Vifor to VFMCRP, so that referenc
